Clinical Studies and Therapies in Parkinson's Disease
Translations from Preclinical Models
- 1st Edition - June 12, 2021
- Imprint: Academic Press
- Author: Juan Segura-Aguilar
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 2 1 2 0 - 4
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 2 1 5 8 - 7
More than 50 years have passed since the use of L-dopa in the palliative treatment of Parkinson’s disease, but it remains the most common treatment despite inducing severe side… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteMore than 50 years have passed since the use of L-dopa in the palliative treatment of Parkinson’s disease, but it remains the most common treatment despite inducing severe side effects such as dyskinesia after 4–6 years of use. Numerous preclinical investigations based on endogenous neurotoxin models have promised various therapies for Parkinson’s disease, but these efforts have failed when attempting to transfer these successful results to preclinical studies. Although several publications have warned of these failures, the scientific community remains mostly unaware, and there is a need to focus their efforts on potential therapeutics that can slow or halt development of the disease.
Clinical Studies and Therapies in Parkinson’s Disease: Translations from Preclinical Models analyzes preclinical models based on exogenous neurotoxins and why they have failed. Neuroscientists, neurologists, and neuropharmacologists will benefit greatly from the book’s discussion of these newer models, their benefits, and the need for their implementation. This book also provides the basic concepts of dopamine metabolism for students taking courses in neurochemistry, neuroscience, neuropharmacology, biochemistry, and medicine.
Clinical Studies and Therapies in Parkinson’s Disease: Translations from Preclinical Models analyzes preclinical models based on exogenous neurotoxins and why they have failed. Neuroscientists, neurologists, and neuropharmacologists will benefit greatly from the book’s discussion of these newer models, their benefits, and the need for their implementation. This book also provides the basic concepts of dopamine metabolism for students taking courses in neurochemistry, neuroscience, neuropharmacology, biochemistry, and medicine.
- Reviews Parkinson's disease classification, pharmacological therapies, and nonmotor and motor symptoms
- Analyzes preclinical models of Parkinson’s disease therapies based on exogenous neurotoxins and why they have failed
- Reviews genetic preclinical models based on genetic mutations and endogenous neurotoxins
- Proposes a more physiological model directly related to the metabolism of dopaminergic neurons
- Provides the basic concepts and mechanisms of dopamine metabolism
Neuroscientists, neurologists, neuropharmarcologists, and students studying neurochemistry, neuroscience, neuropharmacology, biochemistry, and medicine
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Chapter 1. Parkinson's disease
- A. Epidemiology
- B. Parkinson's disease classification
- C. Parkinsonism
- C.2. Paraquat-induced parkinsonism
- C.3. Copper-induced parkinsonism
- C.4. Manganese-induced parkinsonism
- C.5. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine–induced parkinsonism
- D. Idiopathic Parkinson’s disease
- D.1. Nonmotor symptoms
- D.1.1. Olfactory dysfunction
- D.1.2. Rapid eye movement sleep behavior disorder
- D.1.3. Depression
- D.1.4. Constipation
- D.1.5. Excessive daytime somnolence
- D.1.6. Insomnia
- D.1.7. Anxiety
- D.1.8. Cognitive decline
- D.1.9. Parkinson's disease dementia and dementia with Lewy bodies
- D.1.10. Orthostatic hypotension
- D.1.11. Visual disturbances
- D.2. Motor symptoms
- (ii) Alpha-synuclein aggregation to neurotoxic oligomers
- D.2.2. Mitochondrial dysfunction
- D.2.3. Protein degradation dysfunction role in degeneration of nigrostriatal neurons
- D.2.4. Role of oxidative stress in degeneration of nigrostriatal neurons
- D.2.5. Neuroinflammation's role in degeneration of nigrostriatal neurons
- D.2.6. Role of endoplasmic reticulum stress in degeneration of nigrostriatal neurons
- D.3. Diagnosis of idiopathic Parkinson's disease
- E. Genetic Parkinson's disease
- Chapter 2. Parkinson's pharmacological therapy
- Dopaminergic drugs
- Anticholinergic drugs
- Other pharmacological treatments
- New targets and disease-modifying drugs for Parkinson's disease treatment in phase 3
- Drugs in clinical trials
- Chapter 3. Dopamine synthesis
- Tyrosine hydroxylase
- Aromatic amino acid decarboxylase
- Chapter 4. Dopamine storage and release
- Chapter 5. Dopamine oxidative deamination
- Monoamine oxidases
- Monoamine oxidase-B
- Chapter 6. Dopamine methylation
- Catechol ortho-methyltransferase
- Chapter 7. Dopamine oxidation to neuromelanin and neurotoxic metabolites
- Dopamine ortho-quinone
- Aminochrome
- 5,6-Indolequinone
- Dopaminochrome
- Neuromelanin
- Chapter 8. Neuroprotective mechanisms against dopamine oxidation-dependent neurotoxicity
- Vesicular monoamine transporter-2
- DT-diaphorase
- Glutathione transferase-M2-2
- Astrocytes neuroprotection against aminochrome neurotoxicity
- Chapter 9. Exogenous neurotoxins as a preclinical model for Parkinson's disease
- 6-Hydroxydopamine
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- Rotenone
- Exogenous neurotoxin preclinical models for Parkinson's disease
- Chapter 10. Preclinical models based on genetic mutations associated with the familial form of Parkinson's disease
- Chapter 11. Preclinical models based on endogenous neurotoxins
- Alpha-synuclein
- 3,4-Dihydroxyphenylacetaldehyde
- Aminochrome
- Chapter 12. Conclusions
- Index
- Edition: 1
- Published: June 12, 2021
- No. of pages (Paperback): 306
- No. of pages (eBook): 306
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780128221204
- eBook ISBN: 9780128221587
JS
Juan Segura-Aguilar
Dr. Juan Segura-Aguilar, PhD, is a professor of molecular and clinical pharmacology at the University of Chile, Santiago, Chile. He obtained his PhD in biochemistry from Stockholm University, Stockholm, Sweden in 1989. He was previously an associate professor at Uppsala University, Uppsala, Sweden. In 1998, he began as an associate professor at University of Chile, and since 2001 has been a full professor. His research has been focused on mechanisms involved in dopaminergic neuron degeneration in Parkinson´s disease. He has more than 140 publications of his research work on neurodegenerative disorders.
Affiliations and expertise
Professor, University of Chile, Santiago, ChileRead Clinical Studies and Therapies in Parkinson's Disease on ScienceDirect